Skip to search formSkip to main contentSkip to account menu

veltuzumab

A humanized monoclonal antibody directed against the CD20 antigen with potential antineoplastic activity. Following binding, veltuzumab triggers… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
The past three decades have witnessed remarkable advances in our ability to target specific elements of the immune and… 
Review
2017
Review
2017
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined… 
Review
2016
Review
2016
Review
2012
Review
2012
Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with… 
Highly Cited
2011
Highly Cited
2011
Background Subcutaneous injections of anti-CD20 antibodies may offer benefits to both patients and the healthcare system for… 
Review
2010
Review
2010
Veltuzumab is a humanized, anti-CD20 monoclonal IgG1 antibody (MAb), constructed recombinantly on the framework regions of… 
2010
2010
Abstract 2788 Preclinical studies conducted at our institution (Alinari et al. Blood Abstract 1694, 2009) demonstrated superior… 
Highly Cited
2009
Highly Cited
2009
PURPOSE This is a multicenter phase I/II dose-finding study in relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) evaluating… 
Highly Cited
2009
Highly Cited
2009
Veltuzumab is a humanized anti-CD20 monoclonal antibody with complementarity-determining regions (CDRs) identical to rituximab… 
2009
2009
Veltuzumab is a humanized, second-generation anti-CD20 mAb currently under development by Immunomedics Inc for the potential…